Neurogene (NGNE) Return on Sales (2018 - 2025)

Neurogene has reported Return on Sales for 5 years, with the latest figure at 0.92% in Q2 2025.

• For the quarter ending Q2 2025, Return on Sales fell 72.0% year-over-year to 0.92%; the trailing twelve-month figure through Jun 2025 stood at 0.92% (down 24.0% YoY), and the FY2024 full-year result was 0.8%, changed N/A from the prior year.
• Return on Sales for Q2 2025 stood at 0.92%, down from 0.81% in the prior quarter.
• The five-year high for Return on Sales was 0.0% in Q2 2023, with the low at 0.92% in Q2 2025.
• Historically, Return on Sales has averaged 0.38% across 3 years, with a median of 0.2% in 2024.
• The largest YoY upside for Return on Sales was 20 bps in 2024 against a maximum downside of 81 bps in 2024.
• Neurogene's Return on Sales stood at 0.0% in 2023, then sank by 153215 bps to 0.81% in 2024, then fell by 15 bps to 0.92% in 2025.
• The last three Return on Sales figures came in at 0.92% (Q2 2025), 0.81% (Q4 2024), and 0.75% (Q3 2024), per Business Quant data.